Video

Dr. Jadvar shares highlights of appropriate use criteria for PSMA PET imaging

Author(s):

Urology Times staff

“PSMA is a very exciting development in the field of nuclear medicine,” says Hossein Jadvar, MD, PhD.

In this video, Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI, provides an overview of the appropriate use criteria that he helped to develop for prostate-specific membrane antigen PET imaging. Jadvar is a professor of urology and radiology in the Keck School of Medicine at the University of Southern California in Los Angeles.

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Woman talking with doctor | Image Credit: © LuneVA/peopleimages.com - stock.adobe.com
Timothy D. Lyon, MD, answers a question during a video interview
Amy E. Krambeck, MD, answers a question during a Zoom video interview
Related Content
Key FDA decisions urologists can expect in the first half of 2025
January 28th 2025

Key FDA decisions urologists can expect in the first half of 2025

Hannah Clarke
Check out the key regulatory decisions set to happen early this year.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023

Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Urology Times staff
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Incorporating mpMRI in bladder cancer staging may improve time to treatment
January 21st 2025

Incorporating mpMRI in bladder cancer staging may improve time to treatment

Hannah Clarke
The median time to correct treatment was 98 days with initial TURBT vs 53 days with initial mpMRI.
Illuccix approved in Europe for detection of PSMA-positive lesions
January 17th 2025

Illuccix approved in Europe for detection of PSMA-positive lesions

Hannah Clarke
The European approval of Illuccix adds on to prior approvals in the US, Australia, and Canada.
Addition of PSMA PET led to notable stage migration in mHSPC, study shows
January 16th 2025

Addition of PSMA PET led to notable stage migration in mHSPC, study shows

Hannah Clarke
In total, 40.3% of patients experienced a change in staging between initial assessment on conventional imaging and PSMA PET.
Conventional imaging may understage prostate cancer, new data suggest
January 3rd 2025

Conventional imaging may understage prostate cancer, new data suggest

Hannah Clarke
“However, it was informative to uncover such a high number of metastatic findings in a well-defined cohort of patients resembling the EMBARK trial population that was supposed to only include those without metastases," says Adrien Holzgreve, MD, MHA.
© 2025 MJH Life Sciences

All rights reserved.